Recalled Losartan Caused Colon Cancer Diagnosis, Lawsuit Alleges

Exposure to recalled losartan tablets that were contaminated with carinogenic impurities allegedly caused a New York man to develop colon cancer, according to a lawsuit filed against the manufacturer of the generic drug, as well as Walgreens pharmacy, which provided the tainted pills.

The complaint (PDF) was brought by Frank Trimboli in the U.S. District Court for the Eastern District of New York on August 31, indicating that he received versions of the blood pressure drug for treatment of hypertension contaminated with chemicals which resulted in his colon cancer diagnosis in September 2016.

Losartan is supposed to be the generic equivalent for the brand-name blood pressure medication Cozaar. It is part of a class of hypertension treatments known as angiotensin II receptor blockers (ARBs), which have been plagued by generic drug manufacturing problems in recent years that caused pills to be distributed with known human carcinogens.

Learn More About

Valsartan Lawsuits

Side effects of recalled valsartan may increase the risk of cancer, due to an impurity discovered in certain generic versions of the hypertension drug.


Following a number of massive valsartan recalls issued last summer, which impacted most of the U.S. drug supply for that ARB drug, a number of similar recalls have been issued for losartan-based generic medications, including the one used by Trimboli.

Investigations suggest changes in the generic drug manufacturing process resulted in the chemical impurities, including Nitroso-dimethylamine (NDMA), N-Nitrosodiethylamine (NDEA) and other nitrosamine compounds, which are known to increase the risk of cancer.

The losartan lawsuit filed by Trimboli alleges the manufacturers knew or should have known the pills were contaminated, yet continued to sell the medication without warning consumers and the medical community about the potential cancer risk.

“NDMA and NDEA are both considered genotoxic compounds, as they both contain nitroso groups, which are gene-mutating groups,” the lawsuit states. “The pharmaceutical industry has been aware of the potential for the formation of nitrosamines in pharmaceutical drugs at least as far back as 2005.”

The complaint joins a growing number of similar valsartan lawsuits pending in the federal court system by former users of this other recalled drug. Plaintiffs indicate that following long-term exposure to the chemical impurities in their blood pressure drug, they have developed various types of cancer, including stomach cancer, colorectal cancer, liver cancer, pancreatic cancer and other injuries linked to NDMA, NMBA or NDEA.

Image Credit: |


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted yesterday)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 3 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.